By Fineline Cube China’s National Healthcare Security Administration (NHSA) announced that the application period for the 2026 adjustment of the National Basic Medical Insurance, Maternity Insurance, and Workers’ Compensation Insurance Drug List, along with the Commercial Health Insurance Innovative Drug List, concluded on June 10 at 8:00 PM. The agency received a total of 818 drug applications, marking a continued increase from the 2025 cycle.
Application Breakdown
| Category | Number of Applications | Percentage |
|---|---|---|
| Total Applications | 818 | 100% |
| New Drug Applications | 570 | 69.7% |
| Existing Drug Applications | 248 | 30.3% |
New Drug Application Details
| Submission Type | Applications |
|---|---|
| NRDL Only | 509 |
| Commercial Insurance List Only | 17 |
| Both NRDL and Commercial Insurance List | 44 |
| Total New Drugs | 570 |
Year-over-Year Trend
- 2026 Applications: 818 total applications
- 2025 Applications: Lower than 2026 (exact figure not disclosed)
- Growth Trend: Continued year-over-year increase in application volume
- Market Implication: Reflects growing pharmaceutical innovation and manufacturer confidence in China’s reimbursement system
Strategic Significance
The record application volume demonstrates strong industry engagement with China’s dual-track reimbursement system, which now includes both the traditional National Reimbursement Drug List (NRDL) and the newer Commercial Health Insurance Innovative Drug List. This bifurcated approach allows innovative therapies to access different patient populations and payment mechanisms.
Market Impact Analysis
- Pharmaceutical Industry Response: High application numbers indicate manufacturers view NHSA reimbursement as critical for market access and commercial success
- Innovation Focus: Significant portion of new applications (570 out of 818) suggests robust pipeline of novel therapies seeking market entry
- Dual-List Strategy: 44 applications targeting both lists reflect sophisticated market access strategies by pharmaceutical companies
- Competitive Pressure: Increased application volume may intensify price negotiation pressure during the upcoming evaluation and negotiation phases
Next Steps in the Process
- Evaluation Phase: NHSA will conduct clinical and economic evaluations of submitted applications
- Negotiation Period: Price negotiations expected to begin in Q3 2026 for selected candidates
- Final List Announcement: Updated drug lists anticipated for implementation in January 2027
- Commercial Insurance Integration: Parallel review process for commercial health insurance innovative drug list
Broader Healthcare Policy Context
This application cycle occurs against the backdrop of China’s ongoing healthcare reform efforts, which aim to balance patient access to innovative medicines with sustainable healthcare expenditure. The dual-list system represents an evolution in policy design, creating pathways for both cost-effective generics/biosimilars (through NRDL) and premium innovative therapies (through commercial insurance channels).
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory processes and market dynamics. Actual outcomes may differ due to policy changes, evaluation results, and negotiation outcomes.-Fineline Info & Tech